Eris Lifesciences Share News - Latest Updates, Live News & More

Latest news about Eris Lifesciences

Eris Lifesciences Reports Robust Growth: 36% EBITDA Margin in H1FY26 1 day ago

Eris Lifesciences has shown robust financial performance with EBITDA margin increasing from 32% in FY23 to 36% in H1FY26. The company's Q2 FY26 results indicate significant year-over-year growth, with revenue up 6.68% to ₹793.20 crores and net profit surging 39.67% to ₹134.50 crores. Strategic acquisitions, including Biocon's insulin business and Swiss Parenterals, have strengthened its market position. Eris now holds a 6% overall market share and 15% share in insulins, ranking among the top 5 players in anti-diabetes therapy. The company has also secured its first EU-CDMO contract, projecting revenue of ₹150-200 crores in FY27.

Eris Lifesciences Expands Portfolio with ₹4.23 Billion Acquisition of 30% Stake in Swiss Parenterals 10 days ago

Eris Lifesciences to Consider Preferential Share Issue for Swiss Parenterals Acquisition Nov 19, 2025

Eris Lifesciences Reports Q2 FY26 Results, Board Approves Director Reappointments Nov 12, 2025

Novartis Faces Setback as Indian Patent Office Revokes Vymada Patent Sep 16, 2025

More news about Eris Lifesciences

22Aug 25

Eris Lifesciences Faces IGST Non-Payment Allegations, Receives Show Cause Notice

Eris Lifesciences received a show cause cum demand notice from the Directorate General of GST Intelligence, Mumbai, alleging non-payment of IGST on reverse charge mechanism for importing services. The issue relates to the company's acquisition of trademark rights for 'Zomelis' from Novartis AG Switzerland in November 2019. The notice demands ₹16,84,67,040 in IGST, plus 18% per annum interest from November 27, 2019. Eris Lifesciences is evaluating the matter with tax consultants and plans to respond within the prescribed timeframe, asserting its compliance with GST laws and industry practices.

13Aug 25

Eris Lifesciences' Subsidiary Sees Auditor Resignation in Move Towards Group-Level Audit Consolidation

R R S & Associates, the statutory auditor of Eris Therapeutics Limited (ETL), a material subsidiary of Eris Lifesciences, has resigned effective August 12, 2025. The resignation aims to facilitate the appointment of a single auditor for both Eris Lifesciences and ETL, bringing synergies to the audit process and maintaining consistency across the group. The auditor confirmed no material concerns led to their resignation beyond the stated reason of audit consolidation. Eris Lifesciences has informed stock exchanges of this development in compliance with SEBI regulations.

05Aug 25

Eris Lifesciences Posts Robust Q1 Results with 39.7% Surge in Net Profit

Eris Lifesciences reported impressive Q1 financial results. Revenue increased by 7.4% to ₹773.00 crore. Consolidated net profit surged 39.7% to ₹125.10 crore. EBITDA grew to ₹276.00 crore with an improved margin of 35.80%. Key financial ratios show robust health with a Debt-Equity Ratio of 0.74 and Net Profit Margin of 16.18%. Chairman Amit Bakshi approved the results at the board meeting on August 5.

19May 25

Eris Lifesciences Projects Strong Growth: FY26 Revenue Forecast at ₹2,900-3,050 Crore

Eris Lifesciences has released its financial projections for FY26 in an investor presentation. The company aims for revenue between ₹2,900-3,050 crore and EBITDA of ₹1,070-1,130 crore. It expects to maintain a 37% EBITDA margin, indicating strong operational efficiency. These projections reflect the company's confidence in its growth strategies and align with broader expansion trends in the Indian pharmaceutical sector.

19May 25

Eris Lifesciences: Q4 Profit Surges 31%, EBITDA Margin Expands to 36%

Eris Lifesciences announced impressive Q4 financial results, with revenue increasing 27.9% year-over-year to ₹705.00 crore. Net profit grew 31.1% to ₹93.80 crore, and EBITDA margin improved to 36.00%. For the full fiscal year, revenue grew 44% to ₹2,894.00 crore. The company provided guidance for the next fiscal year, projecting consolidated revenue between ₹3,325.00–3,500.00 crore and aiming to reduce net debt to ₹1,800.00 crore.

07Mar 25

Eris Lifesciences Reshuffles Holdings: Transfers Two Subsidiaries to Eris Therapeutics for Rs. 862 Crore

Eris Lifesciences has transferred its 100% holdings in Eris Oaknet Healthcare Private Limited (EOHPL) and Aprica Healthcare Limited (AHL) to Eris Therapeutics Limited (ETL) for Rs. 862 crore. The transaction, agreed on March 6, 2025, is expected to complete by March 31, 2025. EOHPL contributed 3.6% to revenue and 2.0% to net worth, while AHL contributed 3.0% to revenue and 2.5% to net worth in the last financial year. The company also allotted 33,287 equity shares under its ESOP-2021 Scheme, increasing its paid-up share capital to Rs. 13,61,62,569.

06Mar 25

Eris Lifesciences Restructures Holdings: Sells Subsidiaries for Rs 861.9 Crore Amid Q3 Profit Decline

Eris Lifesciences is selling its entire stake in two subsidiaries, Eris Oaknet Healthcare and Aprica Healthcare, to its wholly-owned subsidiary Eris Therapeutics for Rs 861.9 crore. The transaction is part of an internal reorganization to be completed by March 31, 2025. Despite a 49.61% revenue increase to Rs 727.45 crore in Q3 FY2025, the company's net profit fell by 18.61% to Rs 83.63 crore, largely due to a 215% surge in finance costs. Additionally, Eris allotted 33,287 equity shares under its ESOP-2021 scheme, increasing its paid-up share capital to Rs 13,61,62,569.